Liver transplantation

EQS-News: HepaRegeniX publishes data for its first-in-class MKK4 inhibitor HRX-215 for the treatment of acute and chronic liver diseases in Cell

Retrieved on: 
Wednesday, April 10, 2024
Liver, Liver failure, DOI, Cell death, Regeneration, Clinical professor, Colorectal cancer, Transplant, Hepatectomy, Risk, Patient, MKK4, Mayo Clinic, Manuscript, Liver transplantation, Teaching hospital, Human, MAP, Liver regeneration, Hepatocyte, PHLF, Regenerative medicine, Safety, Hepatology, Liver disease, Dietary supplement

HRX-215 is a small molecule inhibitor of Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4).

Key Points: 
  • HRX-215 is a small molecule inhibitor of Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4).
  • "The positive results in terms of safety and tolerability confirm our intention to soon offer a drug that has the potential to revolutionize the treatment of severe liver diseases.
  • The data pave the way for further Phase II studies evaluating the efficacy of HRX-215 in humans," emphasizes Dr. Wolfgang Albrecht, COO of HepaRegeniX.
  • Further, HRX-215 was also able to protect hepatocytes from cell death in a model for acute liver injury.

Appointment of Stephen M. Deitsch as new Chief Financial Officer

Retrieved on: 
Thursday, April 4, 2024
Growth, CFO, Patient, Foot, Liver transplantation, IPO, Ankle, FNA, Management

OXFORD, United Kingdom, April 04, 2024 (GLOBE NEWSWIRE) -- OrganOx , a medical device company which is changing the paradigm in liver transplantation in the US and Europe with its groundbreaking normothermic machine perfusion technology, today announces that Stephen (Steve) M. Deitsch will be joining OrganOx as Chief Financial Officer (“CFO”) on April 8, 2024.

Key Points: 
  • OXFORD, United Kingdom, April 04, 2024 (GLOBE NEWSWIRE) -- OrganOx , a medical device company which is changing the paradigm in liver transplantation in the US and Europe with its groundbreaking normothermic machine perfusion technology, today announces that Stephen (Steve) M. Deitsch will be joining OrganOx as Chief Financial Officer (“CFO”) on April 8, 2024.
  • Steve’s leadership was instrumental in Paragon 28’s successful IPO on the NYSE in the fall of 2021.
  • Prior to Paragon 28, Steve held CFO roles in a range of public and privately held companies in both the US and Europe.
  • Craig Marshall, OrganOx Chief Executive Officer, said, “I am hugely looking forward to working with Steve as our new CFO.

Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update

Retrieved on: 
Friday, March 29, 2024
Research, Data monitoring committee, Cirrhosis, Disease, Metabolism, AASLD, Safety, Patient, Food and Drug Administration, Liver, Mortality, Liver transplantation, Hope, Hepatology, Fibrosis, Clinical trial, Annual report, Therapy, GALT, Pharmacokinetics, Data, DSMB, NASH, Food, Esophageal varices

NORCROSS, Ga., March 29, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2023.

Key Points: 
  • NORCROSS, Ga., March 29, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2023.
  • Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said “We have been focused on advancing our Metabolic Dysfunction-Associated Steatohepatitis (MASH, formerly known as NASH) cirrhosis program.
  • Dr. Jamil’s extensive experience in advanced liver disease, specifically for late-stage cirrhotic patients, is a tremendous asset to our program.
  • These results are included in the Company's Annual Report on Form 10-K, which has been filed with the U.S. Securities and Exchange Commission and is available at www.sec.gov .

Orphan designation: Adeno-associated viral vector containing porphobilinogen deaminase gene Treatment of acute intermittent porphyria, 29/04/2009 Withdrawn

Retrieved on: 
Tuesday, April 9, 2024
Community, Eurostat, Civil service commission, Depression, Diagnosis, Psychosis, Cell, Disease, Seizure, Nervous system, Patient, Committee, Knowledge, Light, Regulation, Anxiety, Liver transplantation, EMA, IRIS, AIP, Human, Urine, European, Skin, COMP, Oxygen, Porphyria, European Commission, Safety, Blood, Marketing, Liver, DSM-IV codes, Medicine, Pharmaceutical industry

Orphan designation: Adeno-associated viral vector containing porphobilinogen deaminase gene Treatment of acute intermittent porphyria, 29/04/2009 Withdrawn

Key Points: 


Orphan designation: Adeno-associated viral vector containing porphobilinogen deaminase gene Treatment of acute intermittent porphyria, 29/04/2009 Withdrawn

Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis

Retrieved on: 
Monday, March 25, 2024
Orphan drug, Primary sclerosing cholangitis, Inflammation, Fast Track, European Patent Organisation, Antibody, PSC, Liver, Liver transplantation, Doctor of Philosophy, CCL24, Fibrosis, Treatment, Therapy, European Patent Convention, CMMB, Patent, Use, Hepatology, FDA, TEL, Pharmaceutical industry

TEL AVIV, Israel, March 25, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics to treat rare fibro-inflammatory diseases with high unmet need, today reported that the European Patent Office has granted a new patent for CM-101, Chemomab’s first-in-class monoclonal antibody that neutralizes CCL24, a novel disease target that has been shown to play a critical role in the processes that drive fibrosis and inflammation. CM-101 is currently being assessed in the global Phase 2 SPRING trial for the treatment of primary sclerosing cholangitis (PSC). Patient enrollment in the trial has been completed, with a topline data readout expected midyear 2024.

Key Points: 
  • CM-101 is currently being assessed in the global Phase 2 SPRING trial for the treatment of primary sclerosing cholangitis (PSC).
  • Patient enrollment in the trial has been completed, with a topline data readout expected midyear 2024.
  • The new European patent covers the use of CM-101 and sequence-related anti-CCL24 antibodies for the treatment of hepatic (liver) diseases, including PSC.
  • Unlike other drugs in development for PSC, CM-101 has a unique dual mechanism of action that simultaneously blocks fibrosis and inflammation.

HepaRegeniX publishes data for its first-in-class MKK4 inhibitor HRX-215 for the treatment of acute and chronic liver diseases in Cell

Retrieved on: 
Thursday, March 14, 2024
Liver, Liver failure, DOI, Cell death, Regeneration, Clinical professor, Colorectal cancer, Transplant, Gesellschaft mit beschränkter Haftung, Hepatectomy, Risk, Patient, MKK4, Mayo Clinic, Manuscript, Liver transplantation, Teaching hospital, Human, MAP, Liver regeneration, Hepatocyte, PHLF, Regenerative medicine, Safety, Hepatology, Liver disease, Dietary supplement

HRX-215 is a small molecule inhibitor of Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4).

Key Points: 
  • HRX-215 is a small molecule inhibitor of Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4).
  • “The positive results in terms of safety and tolerability confirm our intention to soon offer a drug that has the potential to revolutionize the treatment of severe liver diseases.
  • The data pave the way for further Phase II studies evaluating the efficacy of HRX-215 in humans,” emphasizes Dr. Wolfgang Albrecht, COO of HepaRegeniX.
  • Further, HRX-215 was also able to protect hepatocytes from cell death in a model for acute liver injury.

Haemonetics Receives FDA Clearance for New TEG® 6s Global Hemostasis - HN Cartridge

Retrieved on: 
Thursday, April 4, 2024
6S, Heparinoid, Patient, HAE, Liver transplantation, MD, Senior, Hemostasis, Heparin, Cardiopulmonary bypass, Safety, FDA, TEG, Physician, Food, Medical device

This new cartridge extends Haemonetics' TEG 6s viscoelastic testing capabilities to serve fully heparinized patients in adult cardiovascular surgeries/procedures and liver transplantation in both laboratory and point-of-care settings.

Key Points: 
  • This new cartridge extends Haemonetics' TEG 6s viscoelastic testing capabilities to serve fully heparinized patients in adult cardiovascular surgeries/procedures and liver transplantation in both laboratory and point-of-care settings.
  • Haemonetics is planning to release the new Global Hemostasis-HN cartridge for TEG 6s system in the coming months.
  • Overall, over 5,500 clinical data points were used to demonstrate safety and effectiveness of the Global Hemostasis – HN assays.
  • "Our market-leading TEG 6s platform has helped Haemonetics make effective and efficient viscoelastic testing more accessible throughout the world," said Stewart Strong, President, Global Hospital at Haemonetics.

Bridge to Life Announces Abstract Presentations at The European Society for Transplantation's ELITA Summit 2024 in Madrid, Spain, April 18-20, 2024

Retrieved on: 
Tuesday, April 2, 2024
Organ transplantation, Medicine, Surgery, University of Bologna, Liver transplantation, University, Abstract, DCD, Transplant

CHICAGO, April 2, 2024 /PRNewswire/ -- Bridge to Life Ltd, a renowned market leader in organ preservation solutions, today announced the presentation of two accepted abstracts at the 2024 ELITA Summit under the auspices of The European Society for Transplantation.

Key Points: 
  • CHICAGO, April 2, 2024 /PRNewswire/ -- Bridge to Life Ltd, a renowned market leader in organ preservation solutions, today announced the presentation of two accepted abstracts at the 2024 ELITA Summit under the auspices of The European Society for Transplantation.
  • The conference is scheduled to take place in Madrid, Spain, from April 18-20, 2024.
  • 100 Hypothermic Oxygenated Perfusion liver transplants in a Portuguese Centre, Júlio Constantino, MD et al, to be presented by Dulce Diogo, MD, Unidade de Transplantação Hepática de Adultos - Serviço de Cirurgia Geral, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal; Poster viewing session on Thursday 18 April 2024, 19:00 – 20:30.
  • Single center evolution of DCD donor utilization for liver transplantation: from perceived marginality to routine and beyond, Matteo Ravaioli, MD et al, Hepatobiliary and Transplant Surgery, Policlinico Sant'Orsola – IRCCS Azienda Ospedaliero, Universitaria di Bologna, Bologna, Italy; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna (Italy), Bologna, Italy; Poster viewing session on Friday 19 April 2024, 12:45 - 13:45.

American Liver Foundation Celebrates Donate Life Month with New Patient Resources, Programs and Support

Retrieved on: 
Monday, April 1, 2024
American Liver Foundation, Journey, Celebration, Liver disease, Environment, Caregiver, Patient, Social media, News, Liver transplantation, MD, ALF, North Shore University Hospital, Liver, Partner, Fatigue, Sadness, Dentistry

April is Donate Life Month and American Liver Foundation (ALF) has new patient resources, programs and support available to all liver transplant patients and the caregivers supporting them.

Key Points: 
  • April is Donate Life Month and American Liver Foundation (ALF) has new patient resources, programs and support available to all liver transplant patients and the caregivers supporting them.
  • "An informed patient is critically important to making the best decisions about care and ensuring the most favorable outcomes," said Lorraine Stiehl, Chief Executive Officer, American Liver Foundation and caregiver to a transplant recipient.
  • Liver patients, families and loved ones are invited to celebrate the gift of life and the importance of liver transplantation.
  • Throughout Donate Life Month ALF encourages patients, caregivers and organ donors to be part of the national conversation!

American Liver Foundation Statement on FDA Approval of Resmetirom

Retrieved on: 
Thursday, March 14, 2024
HCC, Liver failure, American Liver Foundation, Fatty liver disease, Liver disease, Disease, Caregiver, Risk, Cirrhosis, Inflammation, Chairperson, Patient, Life, Liver transplantation, Hope, Doctor of Philosophy, MASH, MD, ALF, Pharmacotherapy, Fibrosis, NASH, Hepatology, Hepatocellular carcinoma, NAFLD, FDA, Liver, Food, Pharmaceutical industry

FAIRFIELD, N.J., March 14, 2024 /PRNewswire/ -- Today, the Food and Drug Administration (FDA) granted accelerated approval of a first of its kind drug therapy, resmetirom, for the treatment of nonalcoholic steatohepatitis (NASH) in patients who have progressed to fibrosis. NASH, now called metabolic dysfunction-associated steatohepatitis or MASH, is a dangerously progressive form of nonalcoholic fatty liver disease* (NAFLD) and causes inflammation in the liver and liver damage.

Key Points: 
  • NASH, now called metabolic dysfunction-associated steatohepatitis or MASH, is a dangerously progressive form of nonalcoholic fatty liver disease * (NAFLD) and causes inflammation in the liver and liver damage.
  • "American Liver Foundation applauds the FDA approval of the groundbreaking new drug therapy treatment, resmetirom, for patients with NASH who have progressed to fibrosis," said Lorraine Stiehl , Chief Executive Officer, American Liver Foundation.
  • American Liver Foundation offers many free resources to patients and families affected by liver disease.
  • *Note: The nomenclature for NAFLD and NASH recently changed to metabolic dysfunction-associated liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) respectively.